Skip to content

Study · Observational study · 2018

7 results

Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.

Jabbour SA, Frías JP, Guja C, Hardy E, Ahmed A, Öhman P

Diabetes, obesity & metabolism4 Feb 2018Cited by 45 (Europe PMC)

PMID29316164 (opens in a new tab)PMCIDPMC5969082 (opens in a new tab)DOI10.1111/dom.13206 (opens in a new tab)PepBankPUB-29316164
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In T2DM patients receiving exenatide alone, weight loss was numerically greater with higher baseline BMI.

    In plain wordsIn diabetes patients receiving exenatide alone, those with higher starting body mass index lost numerically more weight.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWeight loss by baseline BMI
    Study

    n: not reported in source

    Comparator
    Lower baseline BMI
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    For each treatment, weight loss was numerically greater as baseline body mass index increased.
    1 context sentence
    Title · context
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
  2. 02HumanObservational studyEfficacy outcome

    In T2DM patients receiving exenatide alone, SBP reductions were greater with baseline SBP ≥140 versus <140 mm Hg.

    In plain wordsIn diabetes patients receiving exenatide alone, blood pressure fell more in those with higher starting blood pressure.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSBP reduction by baseline SBP
    Study

    n: not reported in source

    Comparator
    Baseline SBP <140 mm Hg
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    SBP reductions were greater among patients with SBP ≥140 vs <140 mm Hg for exenatide once weekly plus dapagliflozin and exenatide once weekly.
  3. 03HumanObservational studyEfficacy outcome

    In T2DM patients receiving exenatide alone, triglyceride reductions were greater with baseline triglycerides <1.69 versus ≥1.69 mmol/L.

    In plain wordsIn diabetes patients receiving exenatide alone, triglycerides fell more in those with lower starting triglycerides.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTriglyceride reduction by baseline triglycerides
    Study

    n: not reported in source

    Comparator
    Baseline triglycerides ≥1.69 mmol/L
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 28 weeksAs given in this study (human).

    Source sentences

    Summary
    Reductions in triglyceride levels were greater among patients with baseline triglycerides <1.69 vs ≥1.69 mmol/L for each treatment.
    1 context sentence
    Title · context
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.

Studies that did not test the peptide alone4

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 04HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome

    In T2DM, body weight, SBP and triglycerides decreased across most subgroups of all treatments, without significant subgroup-by-treatment interactions.

    In plain wordsIn diabetes, weight, blood pressure and triglycerides decreased across most subgroups of all treatments, including exenatide regimens.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCardiovascular risk factors across subgroups
    Study

    n: not reported in source

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight

    Source sentences

    Summary
    Body weight, SBP and triglyceride levels were reduced across most respective subgroups, with no significant subgroup-by-treatment interactions.
    1 context sentence
    Summary · context
    Subgroups of patients were stratified according to their baseline body weight, SBP and triglyceride levels.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 05HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome

    In T2DM patients receiving exenatide plus dapagliflozin, weight loss was numerically greater with higher baseline BMI.

    In plain wordsIn diabetes patients receiving exenatide plus dapagliflozin, those with higher starting body mass index lost numerically more weight.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCombination weight loss by baseline BMI
    Study

    n: not reported in source

    Comparator
    Lower baseline BMI
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    For each treatment, weight loss was numerically greater as baseline body mass index increased.
    1 context sentence
    Title · context
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 06HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome

    In T2DM patients receiving exenatide plus dapagliflozin, SBP reductions were greater with baseline SBP ≥140 versus <140 mm Hg.

    In plain wordsIn diabetes patients receiving exenatide plus dapagliflozin, blood pressure fell more in those with higher starting blood pressure.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCombination SBP reduction by baseline SBP
    Study

    n: not reported in source

    Comparator
    Baseline SBP <140 mm Hg
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    SBP reductions were greater among patients with SBP ≥140 vs <140 mm Hg for exenatide once weekly plus dapagliflozin and exenatide once weekly.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 07HumanNot a test of Exenatide (exendin-4) aloneObservational studyEfficacy outcome

    In T2DM patients receiving exenatide plus dapagliflozin, triglyceride reductions were greater with baseline triglycerides <1.69 versus ≥1.69 mmol/L.

    In plain wordsIn diabetes patients receiving exenatide plus dapagliflozin, triglycerides fell more in those with lower starting triglycerides.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseCombination triglyceride reduction by baseline triglycerides
    Study

    n: not reported in source

    Comparator
    Baseline triglycerides ≥1.69 mmol/L
    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    Reductions in triglyceride levels were greater among patients with baseline triglycerides <1.69 vs ≥1.69 mmol/L for each treatment.
    1 context sentence
    Title · context
    Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.